Health Technology Assessment of Belimumab: A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus

Table 3

Adverse effects more commonly reported in LBSL02, C1056, and C1057 studies-combined analysis [12].

Symptom	Placebo	Belimumab 1 mg/kg	Belimumab 10 mg/kg
Headache	140 (20.7%)	138 (20.5%)	142 (21.1%)
Upper airways infection	130 (19.3%)	128 (19.0%)	118 (17.5%)
Arthralgia	112 (16.6%)	100 (14.9%)	109 (16.2%)
Nausea	82 (12.1%)	88 (13.1%)	99 (14.7%)
Urinary tract infection	82 (12.1%)	92 (13.7%)	87 (12.9%)
Diarrhea	62 (9.2%)	81 (12.0%)	80 (11.9%)
Asthenia	70 (10.4%)	71 (10.5%)	66 (9.8%)
Pyrexia	52 (7.7%)	52 (7.7%)	65 (9.6%)